Ensysce Biosciences (ENSC) Institutional Ownership $1.76 -0.12 (-6.38%) Closing price 04:00 PM EasternExtended Trading$1.76 +0.00 (+0.28%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Ensysce Biosciences (NASDAQ:ENSC)CurrentInstitutional OwnershipPercentage5.63%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$3.95MNumber ofInstitutional Sellers(last 12 months)0 Get ENSC Insider Trade Alerts Want to know when executives and insiders are buying or selling Ensysce Biosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ENSC Institutional Buying and Selling by Quarter Ensysce Biosciences Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025Adage Capital Partners GP L.L.C.50,000$407K0.0%N/A3.817% 11/15/2024Anson Funds Management LP983,518$236K0.0%N/A11.151% 11/15/2023Sabby Management LLC96,973$134K0.1%-69.9%3.079% 8/14/2023Anson Funds Management LP36,261$65K0.0%N/A2.833% 5/1/2023Virtu Financial LLC13,433$65K0.0%N/A1.049% (Data available from 1/1/2016 forward) ENSC Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ENSC shares? During the previous two years, the following institutional investors and hedge funds held shares of Ensysce Biosciences shares: Adage Capital Partners GP L.L.C. ($407K), Anson Funds Management LP ($236K), and Sabby Management LLC ($134K), Virtu Financial LLC ($65K).Learn more on ENSC's institutional investors. What percentage of Ensysce Biosciences stock is owned by institutional investors? 5.63% of Ensysce Biosciences stock is owned by institutional investors. Learn more on ENSC's institutional investor holdings. Which institutional investors have been buying Ensysce Biosciences stock? The following institutional investors have purchased Ensysce Biosciences stock in the last 24 months: Anson Funds Management LP ($1.02M), Adage Capital Partners GP L.L.C. ($50K), and Virtu Financial LLC ($13.43K). How much institutional buying is happening at Ensysce Biosciences? Institutional investors have bought a total of 1,083,212 shares in the last 24 months. This purchase volume represents approximately $16.69M in transactions. Which Ensysce Biosciences major shareholders have been selling company stock? The following institutional investors have sold Ensysce Biosciences stock in the last 24 months: Sabby Management LLC ($225.33K). How much institutional selling is happening at Ensysce Biosciences? Institutional investors have sold a total of 225,325 shares in the last 24 months. This volume of shares sold represents approximately $4.66M in transactions. Related Companies MBRX Major Shareholders LPTX Major Shareholders MRKR Major Shareholders NXTC Major Shareholders ABVC Major Shareholders TXMD Major Shareholders HCWB Major Shareholders ATHA Major Shareholders NERV Major Shareholders TRIB Major Shareholders This page (NASDAQ:ENSC) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.